AB0946 A META-ANALYSIS TO EVALUATE THE EFFICACY AND SAFETY OF IGURATIMOD ON ACTIVITY AX-SPA

Background Iguratimod is a newly-developed small molecular anti-rheumatic drug, which can inhibit the effects of prostaglandin E2, TNF-α and IL-17. had been reported to be effective in treatment SpA. was implied potential efficacy on ax-SpA. Objectives This study aimed demonstrated safety activity ax-SpA (ASDAS>2.1). Methods We performed meta-analysis systemically evaluate by gathering published RCTs about ax-SpA, mean differences (MD) 95% CI change back pain, morning stiffness, PhGA, ASDAS, BASDAI, BASFI concertation TNF-α, ESR CRP were calculated. Besides, odds ratio (OR) ASAS 20, 40, partial remission ASAS, 5/6 calculated as well. Results 7 admitted into meta-analysis, including 186 cases control group 208 group. The treated with NSAIDs monotherapy or combined DMARDs, range follow-ups 12-24 weeks. improvement pain (MD -1.76, CI: -2.33 ~ -1.20, P<0.001), stiffness -11.27, -13.57 -8.96, PhGA -2.86, -5.45 -0.26, P<0.05), ASDAS -0.8, -1.26 -0.33, BASDAI -1.19, -1.59 -0.78, -0.92, -1.29 -0.55, 20 (OR 11.94, 5.30 26.91, 40 4.46, 1.95 10.16, 17.69, 4.06 77.08, P<0.001) better than those group, well for -8.77, -15.37 -2.18, -4.44, -6.66 -2.23, -6.98, -7.72 -6.24, P<0.01). There no significant difference adverse events between two groups. Conclusion well-tolerated during thus could new pharmaceutical option patients. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.